Skip to Content
Merck
  • Antimicrobial resistance of Listeria monocytogenes strains isolated from humans in France.

Antimicrobial resistance of Listeria monocytogenes strains isolated from humans in France.

Antimicrobial agents and chemotherapy (2010-04-14)
A Morvan, C Moubareck, A Leclercq, M Hervé-Bazin, S Bremont, M Lecuit, P Courvalin, A Le Monnier
ABSTRACT

Susceptibility to antibiotics of 4,816 clinical L. monocytogenes strains isolated since 1926 was studied, and the temporal evolution of susceptibility to antibiotics was analyzed through several decades. The mechanisms of resistance in each resistant strain were studied. The prevalence of resistant strains was estimated at 1.27% among isolates from humans. Resistance to tetracyclines+ and fluoroquinolones was more common and has recently emerged. Although acquired resistance in clinical L. monocytogenes did not implicate clinically relevant antibiotics, the possibility of resistance gene transfers, the description of the first clinical isolate with high-level resistance to trimethoprim, and the recent increase in penicillin MICs up to 2 microg/ml reinforce the need for microbiological surveillance.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Trimethoprim, ≥99.0% (HPLC)
Sigma-Aldrich
Tetracycline, 98.0-102.0% (HPLC)
Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Trimethoprim, ≥98.5%
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.
Supelco
Trimethoprim, VETRANAL®, analytical standard
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Supelco
Ciprofloxacin, VETRANAL®, analytical standard